X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
1. Bumedyl
2. Bumethanide
3. Bumex
4. Burinex
5. Drenural
6. Fordiuran
7. Miccil
8. Pf 1593
9. Pf-1593
10. Pf1593
1. 28395-03-1
2. 3-(butylamino)-4-phenoxy-5-sulfamoylbenzoic Acid
3. Bumex
4. Burinex
5. Fordiuran
6. Lunetoron
7. Fontego
8. Segurex
9. Ro 10-6338
10. Bumetanida
11. Bumetanidum
12. Bumetanidum [inn-latin]
13. Pf 1593
14. Bumetanida [inn-spanish]
15. 3-(aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic Acid
16. Benzoic Acid, 3-(aminosulfonyl)-5-(butylamino)-4-phenoxy-
17. Bumetanide (ro 10-6338)
18. 0y2s3xuq5h
19. Ro-10-6338
20. Mls000028457
21. Chebi:3213
22. Aquazone
23. Butinat
24. Cambiex
25. Diurama
26. Yurinex
27. Benzoic Acid, 3-(butylamino)-4-phenoxy-5-sulfamoyl-
28. Burine
29. 3-butylamino-4-phenoxy-5-sulfamoyl-benzoic Acid
30. 3-butylamino-4-(phenoxy)-5-sulfamoylbenzoic Acid
31. Lixil-leo
32. Ro-106338
33. Ncgc00015149-02
34. Smr000058418
35. Lixil
36. Cas-28395-03-1
37. Ro 10-6338;pf 1593
38. Dsstox_cid_2699
39. 3-butylamino-4-phenoxy-5-sulfamoylbenzoic Acid
40. Dsstox_rid_76695
41. Dsstox_gsid_22699
42. S95008.
43. S-95008.
44. Bufenox
45. Bumex (tn)
46. Sr-01000003062
47. Einecs 249-004-6
48. Unii-0y2s3xuq5h
49. Brn 2185351
50. Bumetanide In Bulk
51. 82u
52. Prestwick_679
53. Mfcd00078949
54. Bumetanide [usan:usp:inn:ban:jan]
55. Spectrum_001317
56. Bumetanide, >=98%
57. Bumetanide [mi]
58. Bumetanide [inn]
59. Bumetanide [jan]
60. Opera_id_1734
61. Prestwick0_000276
62. Prestwick1_000276
63. Prestwick2_000276
64. Prestwick3_000276
65. Spectrum2_001050
66. Spectrum3_001481
67. Spectrum4_000030
68. Spectrum5_001212
69. Bumetanide [usan]
70. Lopac-b-3023
71. Bumetanide [vandf]
72. B 3023
73. Bumetanide [mart.]
74. Cid_2471
75. Bumetanide [usp-rs]
76. Bumetanide [who-dd]
77. Chembl1072
78. Lopac0_000162
79. Schembl27525
80. Bspbio_000152
81. Bspbio_001508
82. Bspbio_003061
83. Kbiogr_000228
84. Kbiogr_000439
85. Kbioss_000228
86. Kbioss_001797
87. 3-(butylamino)-4-phenoxy-5-sulfamoyl-benzoic Acid
88. Mls001148265
89. Divk1c_000034
90. Spectrum1502004
91. Spbio_000980
92. Spbio_002371
93. Bpbio1_000168
94. Bumetanide (jp17/usp/inn)
95. Gtpl4837
96. Bumetanide [ep Impurity]
97. Bumetanide [orange Book]
98. Dtxsid5022699
99. Bdbm25903
100. Hms500b16
101. Kbio1_000034
102. Kbio2_000228
103. Kbio2_001797
104. Kbio2_002796
105. Kbio2_004365
106. Kbio2_005364
107. Kbio2_006933
108. Kbio3_000455
109. Kbio3_000456
110. Kbio3_002561
111. Bumetanide [ep Monograph]
112. Ninds_000034
113. 3-(aminosulfonyl)-5-(butylamino)-4-(phenyloxy)benzoic Acid
114. Bio1_000421
115. Bio1_000910
116. Bio1_001399
117. Bio2_000228
118. Bio2_000708
119. Bumetanide [usp Monograph]
120. Hms1361l10
121. Hms1568h14
122. Hms1791l10
123. Hms1921b20
124. Hms1989l10
125. Hms2089p13
126. Hms2092n03
127. Hms2095h14
128. Hms2230p15
129. Hms3259o08
130. Hms3260b05
131. Hms3374e02
132. Hms3402l10
133. Hms3654b13
134. Hms3712h14
135. Hms3873c13
136. Pharmakon1600-01502004
137. Bcp28485
138. Zinc3813061
139. Tox21_110088
140. Tox21_500162
141. Ccg-40125
142. Nsc758145
143. S1287
144. Akos015896600
145. Tox21_110088_1
146. Ac-8115
147. Cs-1821
148. Db00887
149. Ks-5211
150. Lp00162
151. Nc00550
152. Nsc 758145
153. Nsc-758145
154. Sdccgsbi-0050150.p004
155. Idi1_000034
156. Idi1_033978
157. Smp1_000049
158. Ncgc00015149-01
159. Ncgc00015149-03
160. Ncgc00015149-04
161. Ncgc00015149-05
162. Ncgc00015149-06
163. Ncgc00015149-07
164. Ncgc00015149-08
165. Ncgc00015149-09
166. Ncgc00015149-10
167. Ncgc00015149-11
168. Ncgc00015149-12
169. Ncgc00015149-13
170. Ncgc00015149-15
171. Ncgc00015149-16
172. Ncgc00015149-26
173. Ncgc00022072-03
174. Ncgc00022072-04
175. Ncgc00022072-05
176. Ncgc00022072-06
177. Ncgc00022072-07
178. Ncgc00022072-08
179. Ncgc00260847-01
180. Hy-17468
181. Sbi-0050150.p003
182. Ab00052253
183. Eu-0100162
184. Sw196834-3
185. D00247
186. 3-butylamino-4-phenoxy-5-sulphamyl-benzoic Acid
187. Ab00052253-15
188. Ab00052253-16
189. Ab00052253_17
190. Ab00052253_18
191. 3-n-butylamino-4-phenoxy-5-sulfamyl-benzoic Acid
192. 3-n-butylamino-4-phenoxy-5-sulphamyl-benzoic Acid
193. 395b031
194. A819434
195. Q275926
196. J-017055
197. Sr-01000003062-2
198. Sr-01000003062-4
199. Sr-01000003062-7
200. Brd-k38197229-001-06-7
201. Brd-k38197229-001-17-4
202. 3-(aminosulfonyl)-5-(butylamino)-4-phenoxy-benzoic Acid
203. Z1550648769
204. 3-(butylamino)-4-phenoxy-5-sulfamoylbenzoic Acid.
205. Bumetanide, British Pharmacopoeia (bp) Reference Standard
206. Bumetanide, European Pharmacopoeia (ep) Reference Standard
207. Bumetanide, United States Pharmacopeia (usp) Reference Standard
208. Ro 10-6338; Pf 1593 Pound>>ro-10-6338; Pf1593 Pound>>ro10-6338; Pf-1593
| Molecular Weight | 364.4 g/mol |
|---|---|
| Molecular Formula | C17H20N2O5S |
| XLogP3 | 2.8 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 8 |
| Exact Mass | 364.10929292 g/mol |
| Monoisotopic Mass | 364.10929292 g/mol |
| Topological Polar Surface Area | 127 Ų |
| Heavy Atom Count | 25 |
| Formal Charge | 0 |
| Complexity | 528 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 2 | |
|---|---|
| Drug Name | Bumetanide |
| PubMed Health | Bumetanide |
| Drug Classes | Cardiovascular Agent, Diuretic, Loop |
| Drug Label | Bumetanide is a loop diuretic, available as scored tablets, 0.5 mg (light green), 1 mg (yellow) and 2 mg (peach) for oral administration; each tablet also contains: anhydrous lactose, magnesium stearate, microcrystalline cellulose, corn starch and ta... |
| Active Ingredient | Bumetanide |
| Dosage Form | Injectable; Tablet |
| Route | Injection; Oral |
| Strength | 0.5mg; 2mg; 1mg; 0.25mg/ml |
| Market Status | Prescription |
| Company | Bedford; Ivax Sub Teva Pharms; Hospira; Hikma Maple; Sandoz |
| 2 of 2 | |
|---|---|
| Drug Name | Bumetanide |
| PubMed Health | Bumetanide |
| Drug Classes | Cardiovascular Agent, Diuretic, Loop |
| Drug Label | Bumetanide is a loop diuretic, available as scored tablets, 0.5 mg (light green), 1 mg (yellow) and 2 mg (peach) for oral administration; each tablet also contains: anhydrous lactose, magnesium stearate, microcrystalline cellulose, corn starch and ta... |
| Active Ingredient | Bumetanide |
| Dosage Form | Injectable; Tablet |
| Route | Injection; Oral |
| Strength | 0.5mg; 2mg; 1mg; 0.25mg/ml |
| Market Status | Prescription |
| Company | Bedford; Ivax Sub Teva Pharms; Hospira; Hikma Maple; Sandoz |
For the treatment of edema associated with congestive heart failure, hepatic and renal disease including the nephrotic syndrome.
FDA Label
Treatment of autism spectrum disorder
Bumetanide is a loop diuretic of the sulfamyl category to treat heart failure. It is often used in patients in whom high doses of furosemide are ineffective. There is however no reason not to use bumetanide as a first choice drug. The main difference between the two substances is in bioavailability. Bumetanide has more predictable pharmacokinetic properties as well as clinical effect. In patients with normal renal function, bumetanide is 40 times more effective than furosemide.
Sodium Potassium Chloride Symporter Inhibitors
Agents that inhibit SODIUM-POTASSIUM-CHLORIDE SYMPORTERS which are concentrated in the thick ascending limb at the junction of the LOOP OF HENLE and KIDNEY TUBULES, DISTAL. They act as DIURETICS. Excess use is associated with HYPOKALEMIA and HYPERGLYCEMIA. (See all compounds classified as Sodium Potassium Chloride Symporter Inhibitors.)
Diuretics
Agents that promote the excretion of urine through their effects on kidney function. (See all compounds classified as Diuretics.)
C03CA02
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
C - Cardiovascular system
C03 - Diuretics
C03C - High-ceiling diuretics
C03CA - Sulfonamides, plain
C03CA02 - Bumetanide
Absorption
Bumetanide is completely absorbed (80%), and the absorption is not altered when taken with food. Bioavailability is almost complete.
Route of Elimination
Oral administration of carbon-14 labeled Bumex to human volunteers revealed that 81% of the administered radioactivity was excreted in the urine, 45% of it as unchanged drug. Biliary excretion of Bumex amounted to only 2% of the administered dose.
Clearance
0.2 - 1.1 mL/min/kg [preterm and full-term neonates with respiratory disorders]
2.17 mL/min/kg [neonates receiving bumetanide for volume overload]
1.8 +/- 0.3 mL/min/kg [geriatric subjects]
2.9 +/- 0.2 mL/min/kg [younger subjects]
45% is secreted unchanged. Urinary and biliary metabolites are formed by oxidation of the N-butyl side chain.
60-90 minutes
Bumetanide interferes with renal cAMP and/or inhibits the sodium-potassium ATPase pump. Bumetanide appears to block the active reabsorption of chloride and possibly sodium in the ascending loop of Henle, altering electrolyte transfer in the proximal tubule. This results in excretion of sodium, chloride, and water and, hence, diuresis.
Market Place
